Tech Company Financing Transactions
Allostera Pharma Funding Round
On 7/8/2009, Allostera Pharma landed $14.6 million in Series A funding from BDC Venture Capital, Genesys Capital and iNovia Capital.
Transaction Overview
Company Name
Announced On
7/8/2009
Transaction Type
Venture Equity
Amount
$14,600,000
Round
Series A
Investors
Proceeds Purpose
The proceeds of the financing will be used for the development of Allosteramers(TM), a new class of drugs developed by Allostera scientists that are both highly specific for their targets and designed to be orally bioavailable.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
500 Cartier Blvd. Ouest 135
Laval QC, H7V 5B7
Canada
Laval QC, H7V 5B7
Canada
Phone
Website
Email Address
Overview
Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers(TM). Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers(TM) against different targets primarily focused on inflammation and autoimmunity including APG2305.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Kaufmann
Chief Scientific Officer
Sylvain Chemtob
Co-Founder
Christiane Quiniou
Vice President
Shawn Barney
VP - Bus. Development
Carl Nicolino
Browse more venture capital transactions:
Prev: 7/8/2009: Rapid Micro Biosystems venture capital transaction
Next: 7/9/2009: Sequella venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs